Bioshares Biotechnology Clinical Trials Fund ETF Forecast

Hold candidate since May 16, 2025

The BioShares Biotechnology Clinical Trials ETF price gained 1.60% on the last trading day (Friday, 16th May 2025), rising from $17.50 to $17.78. During the last trading day the ETF fluctuated 1.65% from a day low at $17.58 to a day high of $17.87. The price has fallen in 6 of the last 10 days and is down by -9.05% for this period. Volume fell on the last day by -3 thousand shares and in total, 22 thousand shares were bought and sold for approximately $386.41 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The ETF lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $18.89 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the ETF is expected to fall -17.92% during the next 3 months and, with a 90% probability hold a price between $10.13 and $15.50 at the end of this 3-month period. Do note, that if the ETF price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

BBC Signals & Forecast

There are mixed signals in the ETF today. A sell signal was issued from a pivot top point on Friday, May 02, 2025, and so far it has fallen -9.05%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not. The BioShares Biotechnology Clinical Trials ETF holds buy signals from both short and long-term Moving Averages giving a positive forecast for the ETF. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $17.55 and $17.25. A breakdown below any of these levels will issue sell signals.

Support, Risk & Stop-loss for BioShares Biotechnology Clinical Trials ETF

BioShares Biotechnology Clinical Trials finds support from accumulated volume at $17.54 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This ETF has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the ETF moved $0.290 between high and low, or 1.65%. For the last week the ETF has had daily average volatility of 2.69%.

Our recommended stop-loss: $16.81 (-5.43%) (This ETF has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 10 days ago.)

Trading Expectations (BBC) For The Upcoming Trading Day Of Monday 19th

For the upcoming trading day on Monday, 19th we expect BioShares Biotechnology Clinical Trials Fund to open at $17.74, and during the day (based on 14 day Average True Range), to move between $17.03 and $18.53, which gives a possible trading interval of +/-$0.749 (+/-4.21%) up or down from last closing price. If BioShares Biotechnology Clinical Trials Fund takes out the full calculated possible swing range there will be an estimated 8.42% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $17.54 (1.35%) than the resistance at $18.66 (4.95%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is BioShares Biotechnology Clinical Trials Fund ETF A Buy?

BioShares Biotechnology Clinical Trials holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this ETF since the last evaluation from a Sell to a Hold/Accumulate candidate.

Current score: -0.863 Hold/Accumulate Upgraded

Want to trade but not sure how? Our step-by-step guide can help. Skip the guide? Open account with our trusted broker

Predicted Fair Opening Price

Predicted fair opening price on May 19, 2025 - $17.74 ( 0.206%).